Please assess the completion status of the following clinical trial:

Trial Title: A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has T2DM~* is currently on a stable regimen of gliclazide or glimepiride, either alone or in combination with metformin for ≥ 10 weeks~* has a Visit 1/Screening HbA1C between 7.5% and 11.0%~* is a male, or a female who is highly unlikely to conceive during the study and for 14 days after the last dose of study medication~Exclusion Criteria:~* has a history of type 1 diabetes mellitus or a history of ketoacidosis~* has been treated with any antihyperglycemic therapies other than a sulfonylurea (alone or with metformin) within the prior 12 weeks or has ever~been treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic or analogue~* has a history of intolerance or hypersensitivity, or has any contraindication to sitagliptin, gliclazide/glimepiride, or metformin~* is on a weight loss program and not in the maintenance phase, or has started a weight loss medication or has undergone bariatric surgery within 12 months~* has undergone a surgical procedure within 4 weeks or has planned major surgery during the study~* has a medical history of active liver disease~* has had new or worsening signs or symptoms of coronary heart disease within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder~* has a diagnosis of congestive heart failure with New York Heart Association Class III - IV cardiac status~* has a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 90 mmHg~* has human immunodeficiency virus (HIV)~* has severe peripheral vascular disease~* is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks~* has a history of malignancy ≤ 5 years before the study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer~* has a clinically important hematological disorder (such as aplastic anemia,~myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* is pregnant or breast feeding, or is expecting to conceive or donate eggs during the study, including 14 days after the last dose of study medication~* is a user of recreational or illicit drugs or has had a recent history of drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).